Advertisement

Combined pharmacological treatment of heterozygous familial hypercholesterolemia

  • R. Carmena

Abstract

Combined therapy of heterozygous familial hypercholesterolemia using a non-systemically acting drug (bile acid sequestrants) and a systemically acting one is frequently employed in clinical practice. A brief review of this topic is presented, with particular emphasis on the use of cholestyramine combined with pravastatin, a new HMG CoA reductase inhibitor.

Keywords

Bile Acid Familial Hypercholesterolemia Familial Hypercholesterolemia Hepatic Cholesterol Mevalonic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.-
    Goldstein,JL & Brown,MS. (1989) “Familial hypercholesterolemia”. In: The Metabolic Basis of Inherited Disease, 6th Edition. Eds. C.R. Scriver, A.L. Beaudet, W.S. Sly & D. Valle. McGraw Hill, New York, pp 1215–1250Google Scholar
  2. 2.-
    Slack,J. (1969) “Risks of ischaemic heart-disease in familial hyperlipoproteinemic states”. Lancet 2: 1380–84PubMedCrossRefGoogle Scholar
  3. 3.-
    Sheperd,J, Packard,CJ, Bicker,S, Lawrie,TDW & Morgan, HG. (1980) Cholestyramine promotes receptor-mediated low-density lipoprotein catabolism. N Engl J Med, 302: 1219–1224CrossRefGoogle Scholar
  4. 4.-
    Pappu,AS & Illingworth,DR. (1987) Contrasting effects of lovastatin (mevinolin) and bile acid sequestrants on 24-hour urinary mavalonate in familial hypercholesterolemia (abstract). Arteriosclerosis, 7: 513AGoogle Scholar
  5. 5.-
    The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society (1988). European Heart J. 9:571–600Google Scholar
  6. 6.-
    Illingworth,DR. (1989) “New horizons in combination drug therapy for hypercholesterolemia” Cardiology, 76 (suppl. 1): 83–100PubMedCrossRefGoogle Scholar
  7. 7.-
    Carmena,R, Ascaso,JF, Serrano,S, Martinez-Valls,J & Soriano,P. (1984) “Treatment of heterozygous familial hypercholesterolemia with diet, cholestyramine and probucol”. In: Treatment of Hyperlipoproteinemia. Eds.: L.A.Carlsson & A.G.Olsson. Raven Press, New York, pp 147–150.Google Scholar
  8. 8.-
    Carmena,R, de Oya,M, Franco,M, Martinez,ML, Mata,P, Gomez,JA, Serrano,S, Alvarez-Sala,L, Matesanz,J, Rubio, MJ & Gras,X. (1989) “Treatment of heterozygous familial hypercholesterolemia with pravastatin and/or cholestyramine. The Spanish Multicenter Pravastatin Study”. Atherosclerosis VIII, Excerpta Medica, Amsterdam, pp 757–760Google Scholar
  9. 9.-
    Carmena,R, Serrano,S, Martinez,ML, de Oya,M, Alvarez Sala,L, Franco,M, Gomez,JA, Mata,P, Rubio,MJ & Olivan, J. (1989) “Combined therapy of heterozygous familial hypercholesterolemia with cholestyramine and pravastatin”. (The Spanish Multicenter Pravastatin Study). Abstract Book, 7th Int.Meeting on Atherosclerosis and Cardiovascular Disease Univ. of Bologna, Italy.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • R. Carmena
    • 1
  1. 1.Department of Internal MedicineHospital Clinico UniversitarioValenciaSpain

Personalised recommendations